Anna Cäcilia Ingham1,2, Katrine Kielsen3,4, Hanne Mordhorst1, Marianne Ifversen4, Frank M Aarestrup1, Klaus Gottlob Müller3,4,5, Sünje Johanna Pamp6,7. 1. Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark. 2. Present address: Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark. 3. Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 4. Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 5. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 6. Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark. sjpa@dtu.dk. 7. Present address: Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark. sjpa@dtu.dk.
Abstract
BACKGROUND: Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) exhibit changes in their gut microbiota and are experiencing a range of complications, including acute graft-versus-host disease (aGvHD). It is unknown if, when, and under which conditions a re-establishment of microbial and immunological homeostasis occurs. It is also unclear whether microbiota long-term dynamics occur at other body sites than the gut such as the mouth or nose. Moreover, it is not known whether the patients' microbiota prior to HSCT holds clues to whether the patient would suffer from severe complications subsequent to HSCT. Here, we take a holobiont perspective and performed an integrated host-microbiota analysis of the gut, oral, and nasal microbiota in 29 children undergoing allo-HSCT. RESULTS: The bacterial diversity decreased in the gut, nose, and mouth during the first month and reconstituted again 1-3 months after allo-HSCT. The microbial community composition traversed three phases over 1 year. Distinct taxa discriminated the microbiota temporally at all three body sides, including Enterococcus spp., Lactobacillus spp., and Blautia spp. in the gut. Of note, certain microbial taxa appeared already changed in the patients prior to allo-HSCT as compared with healthy children. Acute GvHD occurring after allo-HSCT could be predicted from the microbiota composition at all three body sites prior to HSCT. The reconstitution of CD4+ T cells, TH17, and B cells was associated with distinct taxa of the gut, oral, and nasal microbiota. CONCLUSIONS: This study reveals for the first time bacteria in the mouth and nose that may predict aGvHD. Monitoring of the microbiota at different body sites in HSCT patients and particularly through involvement of samples prior to transplantation may be of prognostic value and could assist in guiding personalized treatment strategies. The identification of distinct bacteria that have a potential to predict post-transplant aGvHD might provide opportunities for an improved preventive clinical management, including a modulation of microbiomes. The host-microbiota associations shared between several body sites might also support an implementation of more feasible oral and nasal swab sampling-based analyses. Altogether, the findings suggest that the microbiota and host factors together could provide actionable information to guiding precision medicine. Video Abstract.
BACKGROUND:Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) exhibit changes in their gut microbiota and are experiencing a range of complications, including acute graft-versus-host disease (aGvHD). It is unknown if, when, and under which conditions a re-establishment of microbial and immunological homeostasis occurs. It is also unclear whether microbiota long-term dynamics occur at other body sites than the gut such as the mouth or nose. Moreover, it is not known whether the patients' microbiota prior to HSCT holds clues to whether the patient would suffer from severe complications subsequent to HSCT. Here, we take a holobiont perspective and performed an integrated host-microbiota analysis of the gut, oral, and nasal microbiota in 29 children undergoing allo-HSCT. RESULTS: The bacterial diversity decreased in the gut, nose, and mouth during the first month and reconstituted again 1-3 months after allo-HSCT. The microbial community composition traversed three phases over 1 year. Distinct taxa discriminated the microbiota temporally at all three body sides, including Enterococcus spp., Lactobacillus spp., and Blautia spp. in the gut. Of note, certain microbial taxa appeared already changed in the patients prior to allo-HSCT as compared with healthy children. Acute GvHD occurring after allo-HSCT could be predicted from the microbiota composition at all three body sites prior to HSCT. The reconstitution of CD4+ T cells, TH17, and B cells was associated with distinct taxa of the gut, oral, and nasal microbiota. CONCLUSIONS: This study reveals for the first time bacteria in the mouth and nose that may predict aGvHD. Monitoring of the microbiota at different body sites in HSCT patients and particularly through involvement of samples prior to transplantation may be of prognostic value and could assist in guiding personalized treatment strategies. The identification of distinct bacteria that have a potential to predict post-transplant aGvHD might provide opportunities for an improved preventive clinical management, including a modulation of microbiomes. The host-microbiota associations shared between several body sites might also support an implementation of more feasible oral and nasal swab sampling-based analyses. Altogether, the findings suggest that the microbiota and host factors together could provide actionable information to guiding precision medicine. Video Abstract.
Authors: Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink Journal: Biol Blood Marrow Transplant Date: 2015-05-11 Impact factor: 5.742
Authors: Jonathan U Peled; Antonio L C Gomes; Sean M Devlin; Eric R Littmann; Ying Taur; Anthony D Sung; Daniela Weber; Daigo Hashimoto; Ann E Slingerland; John B Slingerland; Molly Maloy; Annelie G Clurman; Christoph K Stein-Thoeringer; Kate A Markey; Melissa D Docampo; Marina Burgos da Silva; Niloufer Khan; André Gessner; Julia A Messina; Kristi Romero; Meagan V Lew; Amy Bush; Lauren Bohannon; Daniel G Brereton; Emily Fontana; Luigi A Amoretti; Roberta J Wright; Gabriel K Armijo; Yusuke Shono; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Ana Alarcon Tomas; Richard J Lin; Lucrecia Yáñez San Segundo; Gunjan L Shah; Christina Cho; Michael Scordo; Ioannis Politikos; Kasumi Hayasaka; Yuta Hasegawa; Boglarka Gyurkocza; Doris M Ponce; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Robert R Jenq; Takanori Teshima; Nelson J Chao; Ernst Holler; Joao B Xavier; Eric G Pamer; Marcel R M van den Brink Journal: N Engl J Med Date: 2020-02-27 Impact factor: 91.245
Authors: Ying Taur; Joao B Xavier; Lauren Lipuma; Carles Ubeda; Jenna Goldberg; Asia Gobourne; Yeon Joo Lee; Krista A Dubin; Nicholas D Socci; Agnes Viale; Miguel-Angel Perales; Robert R Jenq; Marcel R M van den Brink; Eric G Pamer Journal: Clin Infect Dis Date: 2012-06-20 Impact factor: 9.079
Authors: Ernst Holler; Peter Butzhammer; Karin Schmid; Christian Hundsrucker; Josef Koestler; Katrin Peter; Wentao Zhu; Daniela Sporrer; Thomas Hehlgans; Marina Kreutz; Barbara Holler; Daniel Wolff; Matthias Edinger; Reinhard Andreesen; John E Levine; James L Ferrara; Andre Gessner; Rainer Spang; Peter J Oefner Journal: Biol Blood Marrow Transplant Date: 2014-01-31 Impact factor: 5.742
Authors: Anna Cäcilia Ingham; Katrine Kielsen; Malene Skovsted Cilieborg; Ole Lund; Susan Holmes; Frank M Aarestrup; Klaus Gottlob Müller; Sünje Johanna Pamp Journal: Microbiome Date: 2019-09-13 Impact factor: 14.650
Authors: Jonathan L Golob; Steven A Pergam; Sujatha Srinivasan; Tina L Fiedler; Congzhou Liu; Kristina Garcia; Marco Mielcarek; Daisy Ko; Sarah Aker; Sara Marquis; Tillie Loeffelholz; Anna Plantinga; Michael C Wu; Kevin Celustka; Alex Morrison; Maresa Woodfield; David N Fredricks Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Alexa M G A Laheij; Frederik R Rozema; Michael T Brennan; Inger von Bültzingslöwen; Stephanie J M van Leeuwen; Carin Potting; Marie-Charlotte D N J M Huysmans; Mette D Hazenberg; Bernd W Brandt; Egija Zaura; Mark J Buijs; Johannes J de Soet; Nicole N M Blijlevens; Judith E Raber-Durlacher Journal: Microorganisms Date: 2022-03-29